Original Papers Clinical Oncology or Epidemiology

Journal of Cancer Research and Clinical Oncology

, Volume 113, Issue 4, pp 376-378

Reversible arrhythmias observed in patients treated with recombinant alpha2 interferon

  • Silvana MartinoAffiliated withDepartment of Medicine, Wayne State University School of Medicine, and Harper-Grace Hospital
  • , Voravit RatanatharathornAffiliated withDepartment of Medicine, Wayne State University School of Medicine, and Harper-Grace Hospital
  • , Chatchada KaranesAffiliated withDepartment of Medicine, Wayne State University School of Medicine, and Harper-Grace Hospital
  • , Bohumil A. SamalAffiliated withDepartment of Medicine, Wayne State University School of Medicine, and Harper-Grace Hospital
  • , Young Ho SohnAffiliated withDepartment of Medicine, Wayne State University School of Medicine, and Harper-Grace Hospital
  • , Seth A. RudnickAffiliated withDepartment of Medicine, Wayne State University School of Medicine, and Harper-Grace Hospital

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

We have treated 25 patients, 7 with breast cancer and 18 with non-Hodgkin's lymphoma, with recombinant alpha2 interferon. In 5 patients we observed cardiac arrhythmias that were unexpected and required treatment. No deaths have occured that we can attribute to interferon, though 1 patient had to be resuscitated. Age, prior cardiac disease, prior treatment with doxorubicin, and interferon dose appear to be predisposing factors for this toxicity.

Key words

Cardiac toxicity Recombinant alpha2 interferon